ライフサイエンスコーパス: radioresistance

1 MDC1 focus retention and increases NHEJ and radioresistance.

2 rticles to understand possible mechanisms in radioresistance.

3 of VEGF expression, tumor angiogenesis, and radioresistance.

4 whereas Nrf2-inducing drugs did not increase radioresistance.

5 s, invasion, metastasis, chemoresistance and radioresistance.

6 one Puma allele is sufficient to confer mice radioresistance.

7 ved macrophages (BMDMvarphi) increased tumor radioresistance.

8 ized by a high degree of chemoresistance and radioresistance.

9 nhibition of PPP canceled the UCHL1-mediated radioresistance.

10 epair, implicating the PI3K/Akt-1 pathway in radioresistance.

11 been suggested to play a major role in tumor radioresistance.

12 enic progeny, which may contribute to tumour radioresistance.

13 nisms that mediate HIF-1 activation and thus radioresistance.

14 M-MDSC infiltration, which results in tumor radioresistance.

15 osphorylate downstream substrates and confer radioresistance.

16 to de novo and acquired chemoresistance and radioresistance.

17 esis and HSP70 expression is associated with radioresistance.

18 and tensin homologue (PTEN), correlates with radioresistance.

19 n to inhibit the development of LDIR-induced radioresistance.

20 eath, whereas decreasing their levels causes radioresistance.

21 , but these tumors are often associated with radioresistance.

22 a, and cyclin B1 and diminished the adaptive radioresistance.

23 Many melanomas exhibit high levels of radioresistance.

24 of Akt phosphorylation, a known pathway for radioresistance.

25 n of HDJ-2, whereas overexpression conferred radioresistance.

26 eptor (EGFR) activity and is associated with radioresistance.

27 iotherapy remains only palliative because of radioresistance.

28 combine with BCR ligands to promote B-1 cell radioresistance.

29 ing a cytoprotective response and subsequent radioresistance.

30 ivation of ATM, Chk1, and Chk2, and impaired radioresistance.

31 be responsible for the observed increase in radioresistance.

32 a mimicked the effects of Ras-CM to increase radioresistance.

33 correlation between loss of chromosome Y and radioresistance.

34 cells, transformed fibroblasts and mediated radioresistance.

35 effectors, was sufficient to confer partial radioresistance.

36 ctors, was also sufficient to confer partial radioresistance.

37 nt samples and its roles in tumor growth and radioresistance.

38 ne with mutant BRCA2 was linked to increased radioresistance.

39 n-mediated cytotoxicity and thereby to tumor radioresistance.

40 emonstrating that IGF-IR directly influences radioresistance.

41 xtranuclear mechanism for the development of radioresistance.

42 large part, responsible for the deinococci's radioresistance.

43 lism, common in BM, has been associated with radioresistance.

44 mined its role in mesenchymal transition and radioresistance.

45 or 2 (HER2), and hypoxia are associated with radioresistance.

46 ntified as a promoter of glioma stemness and radioresistance.

47 ples confirm a correlation between MRNIP and radioresistance.

48 ular contents potentially conferring dietary radioresistance.

49 tivity to glutaminase inhibitors to overcome radioresistance.

50 NA repair pathways associated with bacterial radioresistance.

51 py (RT) owing to concerns of hypoxia-induced radioresistance.

52 en ensues due to tumor intrinsic or acquired radioresistance.

53 SCs are believed to contribute to chemo- and radioresistance.

54 e to that of miR-24 in NPC tumorigenesis and radioresistance.

55 ising therapeutic strategy for reversing NPC radioresistance.

56 ma is an essential mediator of FGFR1-induced radioresistance.

57 ic responses exerts an independent effect on radioresistance.

58 in, RNF8, which is required for ATDC-induced radioresistance.

59 ting this interaction abrogated ATDC-induced radioresistance.

60 king advantage of the dynamic instability of radioresistance.

61 ing biological processes that promote glioma radioresistance.

62 H1299 and NCI-H460, with different levels of radioresistance.

63 s with poor patient prognosis and chemo- and radioresistance.

64 subset of hypoxic cells that determine tumor radioresistance.

65 inhibited DNA damage responses, and enhanced radioresistance.

66 hich are often characterized by a pronounced radioresistance.

67 pregulated by IR and have been implicated in radioresistance.

68 ing axis in NPC tumor cell growth as well as radioresistance.

69 itically contributes to NPC tumor growth and radioresistance.

70 ions reveal that in addition to their higher radioresistance, a shift from asymmetric to symmetric di

71 The results indicate that radioresistance acquired during radiotherapy treatment m

72 that GPR68 is a key mediator of cancer cell radioresistance activated by acidic tumor microenvironme

73 cinoma MCF+FIR cells that showed a transient radioresistance after exposure chronically to fractionat

74 cellular proliferation, carcinogenesis, and radioresistance, all known to be regulated by the activa

75 otherapy (RT)-mediated tumor suppression and radioresistance, although the exact genetic contexts in

76 Convergent evolution towards radioresistance among genetically distinct groups of org

77 ession of c-JUN in MDA-MB-231 cells promoted radioresistance and abrogated miR-125-mediated radiosens

78 adhesion to fibronectin enhanced tumor cell radioresistance and attenuated the cytotoxic and radiose

79 ver, whether specific miRNAs regulate tumour radioresistance and can be exploited as radiosensitizing

80 racteristics have been linked with increased radioresistance and cancer recurrence.

81 cal relevance of isogenic in vitro models of radioresistance and clarifies the molecular radiation re

82 the cellular population that confers glioma radioresistance and could be the source of tumour recurr

83 ng radiation therapy may contribute to their radioresistance and could be therapeutically targeted.

84 ur cells associated with therapy resistance (radioresistance and drug resistance) are likely to give

85 ylation at both regions severely compromises radioresistance and DSB repair.

86 X phosphorylation and is required for normal radioresistance and efficient accumulation of DNA-damage

87 the importance of PI3K in mediating enhanced radioresistance and have implicated PI3K as a potential

88 Reintroduction of wild-type TTK rescued both radioresistance and HR repair efficiency after TTK knock

89 Schizosaccharomyces pombe hus1 promotes radioresistance and hydroxyurea resistance, as well as S

90 lop novel therapeutic strategies to overcome radioresistance and improve radiosensitivity.

91 terns observed in human tumors and conferred radioresistance and increased invasion in vitro.

92 end-joining (NHEJ) pathway is essential for radioresistance and lymphocyte-specific V(D)J (variable

93 cell lines suggests a distinct mechanism of radioresistance and may represent a critical factor in d

94 d secretion and leads to beta-catenin-driven radioresistance and metastasis, opening new therapeutic

95 urthermore, the previously observed enhanced radioresistance and mutability in WTK1 cells must be att

96 ing radiation (IR) is essential for cellular radioresistance and nonhomologous-end-joining-mediated D

97 f rectal cancer miRs may yield biomarkers of radioresistance and offer treatment targets for resensit

98 0-Gy IR course was associated with increased radioresistance and proliferation, suggesting a role for

99 ponse in cancer stem cells may overcome this radioresistance and provide a therapeutic model for mali

100 herefore drives a pathway that enhances HSPC radioresistance and radiation-induced B-cell malignancie

101 ence for the influence of IGF-IR on cellular radioresistance and response to therapy and raise the po

102 damage signaling pathways contribute to GSC radioresistance and that combined inhibition of cell-cyc

103 aimed at gaining a better understanding of 'Radioresistance and the cell cycle'.

104 icate that ALDH(+) cells contribute to tumor radioresistance and their molecular targeting may enhanc

105 s, activation of NRF2 may lead to chemo- and radioresistance and thus affect patient outcome.

106 We examined whether PTEN deficiency leads to radioresistance and whether this can be reversed by nelf

107 ere used to investigate downstream pathways, radioresistance, and epithelial-to-mesenchymal markers.

108 on, invasion, angiogenesis, chemoresistance, radioresistance, and metastasis.

109 High levels of wild-type IGF-IR conferred radioresistance, and mutational analysis revealed that t

110 is associated with more aggressive behavior, radioresistance, and recurrence of cancer.

111 autocrine signaling through EGFR to increase radioresistance, and the EGFR KI GW572016 acts as a radi

112 in thymus retention, differentiation arrest, radioresistance, and tumor formation in zebrafish.

113 elomere stability, population doubling time, radioresistance, and tumorigenicity in a mouse xenograft

114 The mechanisms underlying tumor radioresistance are manifold and, in part, accredited to

115 cular mechanisms by which CRPC cells acquire radioresistance are unclear.

116 though not all of the signaling pathways for radioresistance are well defined, it is now clear that R

117 TCR ability correlated with radioresistance as cells containing BRCA1 showed both in

118 ed a specific role for FGFR1 in glioblastoma radioresistance as modeled by U87 and LN18 glioblastomas

119 , by using mutant I kappa B alpha, inhibited radioresistance as well as reducing steady-state levels

120 embryo fibroblast cell line, shows much more radioresistance associated with a much stronger G(2) arr

121 Proton treatment also partly reversed the radioresistance associated with mutant KRAS.

122 offers a facile approach for overcoming the radioresistance associated with poorly oxygenated cells.

123 emical inhibitors substantially reversed the radioresistance-associated increase in cell migration.

124 cted to elucidate the molecular mechanism of radioresistance-associated metastatic potential of cervi

125 ctive biomarkers and molecular mechanisms of radioresistance bears promise to improve cancer therapie

126 sult in cell death, and inherent or acquired radioresistance because of genomic alterations or the tu

127 n taxonomic classification, genome size, and radioresistance between cell types studied here support

128 ransformation, in that PI3-K is required for radioresistance but not transformation, whereas MEK and

129 ments antitumor immunity and overcomes tumor radioresistance by altering MDSC differentiation and inh

130 ily, survivin plays a key role in developing radioresistance by mediating apoptosis evasion, promotin

131 ased from irradiated lung cancer cells favor radioresistance by orchestrating the recruitment of IL17

132 orm a therapeutic strategy to overcome tumor radioresistance by targeting cuproptosis.

133 To test this hypothesis, we investigated radioresistance by treating primary BALB/c mouse mammary

134 Restoration of chemo/radioresistance by wild-type, but not D165N Artemis sugg

135 Finally, we demonstrate that Ras-mediated radioresistance can be uncoupled from Ras-mediated trans

136 for nasopharyngeal carcinoma (NPC); however, radioresistance can hinder successful treatment.

137 In contrast to the radioresistance caused by HR restoration through BRCA1 r

138 cued the decreased checkpoint activation and radioresistance caused by L1CAM knockdown, demonstrating

139 To overcome radioresistance, certain drugs have been found to sensit

140 tem cell (CSC) characteristics and chemo- or radioresistance concomitantly through Rac1 activation.

141 ion leads to long-term side effects, whereas radioresistance contributes to tumor recurrence.

142 adder cancer cells increased tumorigenicity, radioresistance, degeneration of reactive oxygen species

143 HK18-IR cells showed increased clonogenic radioresistance [dose-modifying factor (DMF), 1.47], red

144 ) may play a role in promoting breast cancer radioresistance due to its clinical relevance and its co

145 Since these responses contribute to cellular radioresistance, ERBB1, the most extensively studied ERB

146 F2 or 53BP1 attenuates KRAS mutation-induced radioresistance, especially in G1 phase cells.

147 Preliminary data implying a relative radioresistance for TNBC do not imply radiation omission

148 eviously characterized mating-type switching/radioresistance gene, swi10.

149 PprA, a pleiotropic protein involved in radioresistance, has been characterized for its roles in

150 The mechanisms underlying tumour radioresistance have remained elusive.

151 Silencing FGFR1 decreased radioresistance in a manner associated with radiation-in

152 whereas overexpression of WT TRAF2 enhanced radioresistance in a RING ligase-dependent manner.

153 t, tumor cell fate, DNA damage response, and radioresistance in a subset of HOXB9-overexpressing brea

154 IGF1R overexpression is associated with radioresistance in breast cancer.

155 ed approach to investigate the mechanisms of radioresistance in cancer cells and help guide improveme

156 oteomic study on small GTPases that regulate radioresistance in cancer cells.

157 and RALA, were previously shown to modulate radioresistance in cancer cells.

158 both required for efficient end joining and radioresistance in cell-based assays.

159 that high Wnt signalling is associated with radioresistance in colorectal cancer (CRC) cells and int

160 olecular mechanism of Wnt signalling-induced radioresistance in CRC and ISCs, and further unveils the

161 y uncovers a previously unknown mechanism of radioresistance in CRPC, which can be therapeutically re

162 hibitor NU7026, and EGFRvIII fails to confer radioresistance in DNA-PKcs-deficient cells.

163 termine the mechanisms by which Ras mediates radioresistance in epithelial cells, we assessed the imp

164 ent signaling, are required for Ras-mediated radioresistance in epithelial cells.

165 up of NF-kappaB target genes are involved in radioresistance in FIR-treated tumor cells with inactive

166 of concept that FGFR1 targeting can degrade radioresistance in glioblastoma, a widespread problem in

167 en Akt activation, repair of DNA damage, and radioresistance in glioblastoma.

168 s mesenchymal (MES) transdifferentiation and radioresistance in glioma stem cells (GSCs), but molecul

169 eutic efficacy of targeting PAK4 to overcome radioresistance in gliomas.

170 The increase in radioresistance in H2K-BCL-2 transgenic mice has two com

171 FE2L2 mutations are predictive biomarkers of radioresistance in head and neck cancer and confer sensi

172 hondrial MKP1 was responsible for conferring radioresistance in HER2-overexpressing breast cancer cel

173 there is no reliable predictive biomarker of radioresistance in HNSCC.

174 e 2-nitroimidazole, Etanidazole, can predict radioresistance in individual tumors.

175 However, radioresistance in irradiated tumors can also develop, r

176 ular target to overcome a novel mechanism of radioresistance in KRAS-mutant tumor cells, which stands

177 on-induced HIF-1alpha and thus to circumvent radioresistance in lung cancer cells.

178 as necessary or sufficient for Ras-mediated radioresistance in matched pairs of RIE-1 rat intestinal

179 Radioresistance in MCF+FIR and MCF+SOD cells was reduced

180 ation leads to spontaneous tumorigenesis and radioresistance in Mdm2(S394A) mice.

181 yclin B1 contribute to LDIR-induced adaptive radioresistance in mouse skin epithelial cells.

182 a critical role in DNA damage signaling and radioresistance in pancreatic cancer cells.

183 e mechanism by which CS-GRP78 contributes to radioresistance in pancreatic ductal adenocarcinoma (PDA

184 a selective advantage in the development of radioresistance in prostate cancer.

185 anism was further confirmed by the increased radioresistance in PrxII-overexpressing MCF+FIS4 cells w

186 h factor receptor (EGFR) also contributes to radioresistance in Ras-transformed cells.

187 ppaB are required for transformation but not radioresistance in RIE-1 epithelial cells.

188 sion and activity frequently correlates with radioresistance in several cancers, including non-small

189 kappaBeta protein complex has been linked to radioresistance in several cancers.

190 wild-type p53 cell line exhibited a greater radioresistance in terms of clonogenic survival.

191 pression in astrocytes also led to increased radioresistance in that cell type.

192 Induced radioresistance in the surviving cancer cells after radi

193 pears to completely reverse the hypoxic cell radioresistance in this tumor model.

194 ng TMs, which were associated with increased radioresistance in those small tumors.

195 Radioresistance, in fact, is such a common feature in fu

196 Ras-dependent signaling pathways involved in radioresistance include those mediated by phosphatidylin

197 mechanisms, which link tumor progenitors to radioresistance, including activation of the WNT/beta-ca

198 e hyper-radiosensitivity (HRS) and increased radioresistance (IRR).

199 Radioresistance is a major cause of decreasing the effic

200 is essential for post-surgery treatment, but radioresistance is a significant challenge contributing

201 However, radioresistance is a significant factor in treatment fai

202 Enhanced radioresistance is abrogated by the DNA-PKcs-specific in

203 against this tumor, local recurrence due to radioresistance is an important clinical problem.

204 a a heterologous viral promoter, near normal radioresistance is conferred on the cells.

205 ly be used to radiosensitize tumors in which radioresistance is dependent on Ras-driven autocrine sig

206 This enhanced radioresistance is due to accelerated repair of DNA doub

207 However, how radioresistance is linked to metabolic reprogramming rem

208 Their radioresistance is not caused by reduced susceptibility

209 nation deficits in DNA-PKcs-deficient cells, radioresistance is not restored.

210 Inherent radioresistance is not shared by splenic B-2 or B-1 cell

211 es show that the ability of BRCA1 to promote radioresistance is restricted to the late S and G2 phase

212 Radioresistance is thought to be a major consequence of

213 allel signaling components contribute to GSC radioresistance is unclear.

214 To understand the radioresistance mechanisms in NSCLC, we focused on the r

215 eptor fusion protein (Enbrel), revealed that radioresistance mediated by BMDMvarphi required intact T

216 on was paralleled by decreased expression of radioresistance mediators.

217 aB is responsible for a major portion of the radioresistance observed in a cell population (HK18-IR)

218 We conclude that the great radioresistance of bdelloid rotifers is a consequence of

219 cells subjected to HFR and implicate Rac1 in radioresistance of breast cancer cells.

220 ed as a novel HIF-1 activator, increased the radioresistance of cancer cells by producing an antioxid

221 taple approach for cancer treatment, whereas radioresistance of cancer cells remains a substantial cl

222 r-derived somatic FOXP3 mutant increased the radioresistance of cancer cells.

223 In addition, the radioresistance of CD133-positive glioma stem cells can

224 repair, thereby promoting the extraordinary radioresistance of D. radiodurans.

225 A revised model is proposed for Gam-induced radioresistance of E. coli to ionizing radiation.

226 Radioresistance of EBV-associated nasopharyngeal carcino

227 proliferation may contribute to the clinical radioresistance of GBM tumors, the combination of rapamy

228 signaling and DSB repair, and also increases radioresistance of glioma cells.

229 ion (IR) has been attributed to the relative radioresistance of glioma-initiating cells (GIC).

230 rovides the most effective means to overcome radioresistance of GSC.

231 ugments DNA damage checkpoint activation and radioresistance of GSCs through L1-ICD-mediated NBS1 upr

232 that selective cellular quiescence increases radioresistance of human cell lines in vitro and mice in

233 The observed radioresistance of human glioblastoma multiforme (GBM) p

234 for cell-fibronectin interactions to induce radioresistance of human non-small cell lung cancer cell

235 rtance of local angiotensin II in regulating radioresistance of hypoxic tumor cells.

236 mice has two components: an increase in the radioresistance of individual cells and, to a lesser ext

237 Radioresistance of KO fibroblasts was associated with ac

238 BXI-72 overcomes acquired radioresistance of lung cancer.

239 s self-renewal, motility, tumorigenesis, and radioresistance of MES GSCs via a loss of the MES signat

240 vival and proinflammatory genes, and in vivo radioresistance of mouse xenograft models.

241 re oncogenic drivers and are correlated with radioresistance of multiple cancers, including colorecta

242 he genesis, malignant progression, and chemo/radioresistance of multiple human malignancies, includin

243 icine (TOM) compound was found to reduce the radioresistance of NSCLC by inhibiting the nuclear facto

244 nce of IL costimuli account for the inherent radioresistance of peritoneal B-1 B cells.

245 t may partly account for the relatively high radioresistance of plants versus yeast and mammals.

246 ates ionizing radiation (IR)-induced PMT and radioresistance of PN GSCs.

247 els of Prx4 contribute to the malignancy and radioresistance of prostate cancer through the activatio

248 cells, which is consistent with the relative radioresistance of S-phase cells as measured with cell s

249 Because of the radioresistance of some human cancers, particularly glio

250 anged balance and mechanisms of differential radioresistance of T cell subsets after graded doses of

251 oietic stem cells (HSC), thus increasing the radioresistance of the animal.

252 ) gene substantially increased the intrinsic radioresistance of the DNA-PKcs(-/-) tumor cells and sub

253 antation experiments show that the increased radioresistance of the transgenic animals is provided by

254 1, NGFIA binding protein 1 (NAB1), increased radioresistance of these cells.

255 astoma and locally advanced lung cancer, but radioresistance of these two types of cancer remains a s

256 n implicated as a contributing factor to the radioresistance of tumor cells.

257 but its treatment efficacy is limited by the radioresistance of tumor cells.

258 t meiosis, which contrasts with its reported radioresistance of up to 1,000 Gy in survival assays.

259 These findings suggest that the radioresistance of villus enterocytes is not simply due

260 mutant I kappa B alpha was unable to inhibit radioresistance or reduce 14-3-3 zeta, GADD153, cyclin A

261 tion of NF-kappaB with other key elements in radioresistance, particularly with respect to extracellu

262 on-induced Notch-1 signaling associated with radioresistance possibly via miR-34a-mediated pathways.

263 hat YAP accelerates tumor growth and confers radioresistance, promoting ongoing proliferation after r

264 To determine whether this radioresistance reflects withdrawal from the cell cycle,

265 ar mechanisms linking the reprogramming with radioresistance remain to be determined.

266 ancreatic cancer, but pancreatic cancer cell radioresistance remains a serious concern.

267 , the molecular mechanisms underlying cancer radioresistance (RR) as well as the biological signature

268 However, mice lacking CD47 showed radioresistance similar to thrombospondin-1-null mice.

269 ray) in human keratinocytes with an adaptive radioresistance that can be inhibited by short interferi

270 However, radioresistance that contributes to recurrence remains a

271 molecular pathways of LDIR-induced adaptive radioresistance, the transcription factor nuclear factor

272 Despite the implication of Wnt signalling in radioresistance, the underlying mechanisms are unknown.

273 ecause quiescence is usually associated with radioresistance, these cell kinetic changes suggest that

274 hus, whereas Raf contributes to Ras-mediated radioresistance, this is accomplished through a MEK-inde

275 reatment may result in therapy-induced tumor radioresistance through ATM- and USP51-mediated activati

276 e development of in vitro isogenic models of radioresistance through exposure to fractionated radiati

277 Nrf2E79Q enhanced radioresistance through increased recruitment of intratu

278 GFRvIII), a common mutation in GBM, promotes radioresistance through ligand-independent activation.

279 that cancer stem cells contribute to glioma radioresistance through preferential activation of the D

280 lular heterogeneity and dynamically acquired radioresistance to predict the effectiveness of differen

281 l tumors of patients unresponsive to RT link radioresistance to the downregulation of BTB and CNC hom

282 Minimal to no upregulation of radioresistance (Trex1 and STAT1), cancer stemness (Nano

283 ated isogenic 22Rv1 prostate cancer model of radioresistance using DigiWest multiplex protein profili

284 ome a prerequisite for overcoming chemo- and radioresistance using radiosensitizing drugs or hypoxia-

285 n a nuclease-independent manner but enhanced radioresistance via a nuclease-dependent pathway.

286 Radioresistance was also observed in normal prostate cel

287 ncreased radiosensitivity, whereas increased radioresistance was observed in human breast cancer MCF-

288 Clonogenic radioresistance was reduced greatly in the mIkappaB tran

289 ated with radiotherapy, can induce increased radioresistance, we have asked which Ras effector pathwa

290 of cIAP1/cIAP2 in lymph node metastasis and radioresistance, we use an in vitro pre-clinical model a

291 tly test the link between Akt activation and radioresistance, we utilized PTEN-deficient U251 gliobla

292 ntaining BRCA1 showed both increased TCR and radioresistance, whereas cells without BRCA1 showed decr

293 nner, indicating that PI3-K is necessary for radioresistance, whereas inhibition of NF-kappaB with th

294 squamous cell carcinoma (HNSCC) patients but radioresistance, which depends on DNA damage response (D

295 e the CRAF/CHK2 association enhancing tumour radioresistance, while an allosteric CRAF inhibitor sens

296 verexpression of wild-type Artemis increased radioresistance, while D165N overexpression conferred pa

297 25C/Cdc2 pathway is the major player for the radioresistance with G(2) arrest in A1-5 cells.

298 Caffeine or UCN-01 abolishes the extreme radioresistance with the strong G(2) arrest and at the s

299 demonstrate an association of acquired tumor radioresistance with up-regulation of components of the

300 he development of drugs that can reduce that radioresistance would potentiate the efficacy of radiati